key: cord-0763043-97pq3txj authors: Saha-Chaudhuri, P title: The Logistics of “Making the Best Use of Test Kits for COVID-19”: Testing More to Test Less date: 2020-07-24 journal: Am J Epidemiol DOI: 10.1093/aje/kwaa128 sha: a8c776f7438ae65ac6b05898958fd50f28933559 doc_id: 763043 cord_uid: 97pq3txj nan I read with interest the timely editorial on specimen pooling [1] in the COVID-19 era. Given the limited availability of the test kits to identify patients with COVID-19 in community settings, pooling (group testing) is becoming more relevant [2] [3] [4] . However, before wider use of pooling to test for SARS-CoV-2 can be recommended, we need to be aware of the potential pitfalls that may impact successful implementation of pooling. It is critical to ensure that the test used with pooled specimens has both high sensitivity and high specificity. If relaxed restrictions are recommended as a policy for those judged to be negative, we need to be confident about declaring a person COVID-19-free in a community setting. Therefore, it is imperative that the current tests, whether it is the RT-PCR test or the rapid test, has high specificity and high negative predictive value. In a low disease prevalence and high test sensitivity setting, high specificity also implies a high NPV. However, the high rate of asymptomatics, overlap of symptoms with other respiratory dieases and a paucity of definitive diagnostic test [5] complicate prevalence estimation for COVID-19. The reported community prevalence ranges anywhere from 0.4% [6] to 5% [7, 8] , but reliable prevalence estimate remains elusive. Additionally, some diagnostic tests are reported to have abysmally low test sensitivity, especially during the critical 14-days window after symptom onset [9, 10] making them unsuitable for pooling. This means that a high test accuracy and low prevalence would be required for successful application of pooling, implying that pooling specimens from high-risk individuals such as the ones in the long-term managed health-care settings (either as a patient or as a caregiver), even with a highly specific test, would be ill-advised. Instead, pooling should be reserved for low prevalence setting with an accurate test to ensure that test-negatives are indeed highly likely negative for COVID-19 [11] . This issue is also intimately tied with limit of detection (LOD) [12] . The viral material is typically more diluted in pooled specimen than a single positive specimen, especially in lower prevalence settings. Therefore, depending on the LOD, a test may incorrectly declare a pooled assay, consisting of a positive specimen, as negative. Thus, the assay LOD should also be taken into account when guiding pooling design. When performing pooling, the objective is to save resources, be it time or precious test kits. The points highlighted above means that only some testes, (e.g., the COVID-19 RT-qPCR test [3, 13] ) would be an ideal candidate for pooling while the rapid tests for COVID-19 [14, 15] and the test for antibodies [16] may not be good candidates. In view of these issues, pilot studies should be done first in the intended settings, with known infection status of individual specimen. Furthermore, for individual laboratories, it is crucial to "validate any modifications to the testing process before universal adoption" [3] , so that we can be confident that the pooling performs exactly as expected. Therefore, we need to perform more testing up-front to ensure the validity and accuracy of pooled testing. Given the limited supply of testing kits and reagents, this is perhaps not encouraging at the face-value. However, to make optimal use of limited test kits, this is a crucial step and one that cannot and should not be skipped. The success of pooled testing is dependent on the fact that pooled test should accurately reveal SARS-CoV-2 infection status. Once we are confident, we can employ pooled testing more widely even within the current limitations. Therefore, we have to bear the cost of more testing right now to be able to ultimately use less testing successfully in the near future. Editorial: Making the Best Use of Test Kits for COVID-19 Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources Evaluation of COVID-19 RT-qPCR test in multi-sample pools Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2 Should RT-PCR be considered a gold standard in the diagnosis of Covid-19? [available online ahead of print May 8 Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers at the onset of the U.S. COVID-19 epidemic Preprints Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults Community Prevalence of SARS-CoV-2 Among Patients With Influenzalike Illnesses Presenting to a Los Angeles Medical Center False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications Clinical Performance of Two SARS-CoV-2 Serologic Assays Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected coronavirus disease 2019 presenting to the hospital To pool or not to pool, from whether to when: applications of pooling to biospecimens subject to a limit of detection Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2